Outcome of the Board Meeting held on May 20, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors of Ganga Pharmaceuticals Ltd approved the audited financial results for the half year and full year ended March 31, 2025. Revenue from operations stood at Rs. 263.74 lakhs, down about 3.6% from Rs. 273.58 lakhs in the previous year. However, total income rose to Rs. 307.33 lakhs from Rs. 297.53 lakhs, aided by higher other income. Net profit jumped sharply to Rs. 7.90 lakhs from Rs. 4.66 lakhs, a growth of roughly 70%, while profit before tax climbed to Rs. 9.47 lakhs from Rs. 6.33 lakhs. Basic EPS improved to Rs. 0.16 from Rs. 0.11. Statutory auditors Banka & Banka issued an unmodified (clean) opinion on the results, with no key audit matters reported. Cash and bank balances strengthened significantly to Rs. 30.24 lakhs from Rs. 2.98 lakhs.
Profitability improved sharply on better cost control and higher other income, even though core operating revenue slipped marginally. The clean auditor opinion and stronger cash position are reassuring for shareholders, but the flat-to-declining top line suggests the underlying business growth remains modest.